CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biopharmaceutical company focused on the development of chimeric engulfment receptor T-cell (CER-T) therapies targeting solid tumor cancers. The company became publicly traded through a business combination with Phoenix Biotech Acquisition Corp (PBAX), a SPAC sponsored by Phoenix Biotech Sponsor LLC, with the merger closing in 2023. Operating in the oncology and cell-therapy sector, CERO filed a 424B3 prospectus supplement with the SEC on August 14, 2026, as the company continues its post-merger public market lifecycle. For complete filing history, cap-table data, and deal analytics on CERO and hundreds of other SPAC transactions, sign up for full access at SpacDesk.